Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer


Acquired | Acquired

About Fairhaven Pharmaceuticals

Fairhaven is a pharmaceutical company focused on developing novel, small molecule, oral therapeutics for severe inflammatory conditions.On July 17, 2020 Fairhaven Pharmaceuticals was acquired by Liminal BioSciences for $5.89 million.

Fairhaven Pharmaceuticals Headquarter Location

Vancouver, British Columbia,


Latest Fairhaven Pharmaceuticals News

BRIEF—Liminal BioSciences broadens R&D pipeline with Fairhaven acquisition

Jul 17, 2020

Clinical-stage Canadian biopharma company Liminal BioSciences today announced that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals, thus acquiring a pre-clinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases through tissue repair and resolution of inflammation. Under the terms of the acquisition, the Company will satisfy the aggregate purchase price of up to C$8 million ($5.9 million) by the issuance of common shares in the capital of Liminal BioSciences to the shareholders of Fairhaven

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.